688520 Stock Overview
A biotech company, engages in the research and development, and industrialization of recombinant proteins, monoclonal antibodies, and vaccines in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Sinocelltech Group Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥37.80 |
| 52 Week High | CN¥55.87 |
| 52 Week Low | CN¥31.07 |
| Beta | 0.61 |
| 1 Month Change | -6.39% |
| 3 Month Change | 17.65% |
| 1 Year Change | -28.75% |
| 3 Year Change | -33.22% |
| 5 Year Change | n/a |
| Change since IPO | -48.27% |
Recent News & Updates
Shareholder Returns
| 688520 | CN Biotechs | CN Market | |
|---|---|---|---|
| 7D | -1.2% | -4.9% | -3.5% |
| 1Y | -28.7% | -17.6% | 10.9% |
Return vs Industry: 688520 underperformed the CN Biotechs industry which returned -17.6% over the past year.
Return vs Market: 688520 underperformed the CN Market which returned 10.9% over the past year.
Price Volatility
| 688520 volatility | |
|---|---|
| 688520 Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in CN Market | 12.8% |
| 10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 688520 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 688520's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 2,348 | Liangzhi Xie | www.sinocelltech.com |
Sinocelltech Group Limited, a biotech company, engages in the research and development, and industrialization of recombinant proteins, monoclonal antibodies, and vaccines in China. The company offers AnpingxiA (repertuzumab injection), an anti-tumor product; Anjiayin for the treatment of the rare disease hemophilia A; coronavirus 2-valent, a trimer protein vaccine; and mutant strain recombinant protein vaccines SCTV01C and SCTV01E. Its pipeline products include SCT630 used for the treatment of autoimmune diseases; SCT510 for the treatment of solid tumors; SCT-I10A, a monoclonal antibody injection which is in phase 3 trials for the treatment of solid tumors; SCTV01, a new generation vaccine which is in phase 3 trials for the treatment of corona virus; SCT510 for the treatment of solid tumors; SCT200, a monoclonal antibody injection for the treatment of solid tumors; and SCT1000, which is in phase 3 clinical trials for the treatment of human papillomavirus, as well as SCTA01 which is in phase 2/3 clinical research trials for the treatment of SARS COV-2.
Sinocelltech Group Limited Fundamentals Summary
| 688520 fundamental statistics | |
|---|---|
| Market cap | CN¥16.83b |
| Earnings (TTM) | -CN¥26.10m |
| Revenue (TTM) | CN¥2.45b |
6.9x
P/S Ratio-645.0x
P/E RatioIs 688520 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688520 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.45b |
| Cost of Revenue | CN¥139.01m |
| Gross Profit | CN¥2.31b |
| Other Expenses | CN¥2.33b |
| Earnings | -CN¥26.10m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.059 |
| Gross Margin | 94.31% |
| Net Profit Margin | -1.07% |
| Debt/Equity Ratio | -1,974.4% |
How did 688520 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 03:25 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Sinocelltech Group Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | China International Capital Corporation Limited |
| Ziyu He | China International Capital Corporation Limited |
| Yizheng Yang | China International Capital Corporation Limited |